Oxford Biomedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. Our technology platforms include a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, we have a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb and Immune Design Corp.
Type
Public
HQ
Oxford, GB
Founded
1995
Employees
192 (est)
Oxford Biomedica was founded in 1995 and is headquartered in Oxford, GB

Oxford Biomedica Locations

Oxford, GB

Oxford Biomedica Metrics

Oxford Biomedica Summary

Market capitalization

£101 M

Closing share price

£0.0392
Oxford Biomedica's latest market capitalization is £101 M.

Oxford Biomedica Financials

Oxford Biomedica's revenue was £15.9 M in FY, 2015 which is 16.82% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

£5.38 M£13.6 M£15.9 M

Revenue growth, %

153.4%16.8%

Cost of sales

£1.14 M£4.42 M£5.84 M

Gross profit

£4.24 M£9.2 M£10.1 M

Gross profit Margin, %

78.8%67.6%63.3%

Operating expense total

£17.1 M£19.8 M£24.2 M

Oxford Biomedica Market Value History

Oxford Biomedica News

Oxford Biomedica Company Life

You may also be interested in